Autophagy-lysosome pathway convergence across neurodegenerative diseases

PARTIALLY ADDRESSED

Multiple NDDs converge on autophagy-lysosome dysfunction. Are there universal therapeutic targets?

Priority: 0.87 Domain: neurodegeneration Hypotheses: 5
📊 Landscape Analysis

Landscape Summary: Autophagy-lysosome pathway convergence across neurodegenerative diseases is a 0.87 priority gap in neurodegeneration. It has 5 linked hypotheses with average composite score 0.670. Status: partially_addressed.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Autophagy-lysosome pathway convergence across neurodegenerative diseases — INVOKE-2 (completed)

📈 Living Dashboards
5
Hypotheses
0.777
Top Score
0.670
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)
Transcriptional Autophagy-Lysosome Coupling
Target: FOXO1 Pathway: Autophagy-lysosome pathway
0.777
score
Autophagosome Maturation Checkpoint Control
Target: STX17 Pathway: Autophagy-lysosome pathway
0.709
score
Microbiota-Microglia Axis Modulation
Target: Multiple Pathway: N/A
0.651
score
Perinatal Immune Challenge Prevention
Target: Multiple Pathway: N/A
0.616
score
VCP-Mediated Autophagy Enhancement
Target: VCP Pathway: Autophagy-lysosome pathway
0.595
score
🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed
📈 Microbiota-Microglia Axis Modulation score=0.651 2026-04-04T13:12
📈 Perinatal Immune Challenge Prevention score=0.616 2026-04-04T13:12
📈 Transcriptional Autophagy-Lysosome Coupling score=0.777 2026-04-02T01:34
📈 Autophagosome Maturation Checkpoint Control score=0.709 2026-04-02T01:34
📈 VCP-Mediated Autophagy Enhancement score=0.595 2026-04-02T01:01
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps